Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography

Meissner, Valentin H.; Rauscher, Isabel; Schwamborn, Kristina; Neumann, Jan; Miller, Gregor; Gschwend, Jürgen E.; Eiber, Matthias; Heck, Matthias

doi:10.1016/j.eururo.2021.11.019

Cited by 61 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the future, our research group will introduce robot positioning system into the SPPB to perform more accurate targeted biopsy for patients. In addition, it has been reported patients with high suspicion of prostate cancer on prostate-specific membrane antigen positron emission tomography (PSMA-PET) and mpMRI were directly treated with a radical prostatectomy without prior biopsy (25). Therefore, our research group intends to apply PSMA-PET to elderly patients with PIRADS 5 lesions, to explore whether patients with PSMA-PET showing the possibility of prostate cancer can be directly treated with antitumor therapy without experiencing the pain and risk of operation.…”

Section: Discussionmentioning

confidence: 99%

Application of single-point prostate biopsy in elderly patients with highly suspected prostate cancer

Luan

Xiao²,

Ding³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo explore the feasibility of single-point prostate biopsy in elderly patients with highly suspected prostate cancer.MethodsForty-three patients with a prostate imaging reporting and data system score (PI-RADS) of 5, age ≥ 80 years and/or PSA ≥ 100 ng/ml and/or Eastern Cooperative Oncology Group score ≥ 2 were enrolled in our hospital from March 2020 to June 2022. Targeted surgery of these patients was performed using only precise local anesthesia in the biopsy area. The biopsy tissues were examined by intraoperative frozen section examination (IFSE). If the result of IFSE was negative, traditional systematic biopsy and further routine pathological examination were performed. The positive rate of biopsy, operation time, complications and pain score were recorded.ResultsThe positive rate of prostate biopsy was 94.7%. The results of IFSE in two patients were negative, and the routine pathological results of further systematic biopsy of those patients were also negative. The visual analog scale and visual numeric scale were 2 (2-4) and 3 (2-3), respectively, during the biopsy procedure. The mean time of operation was 8.5 ± 2.1 min from the beginning of anesthesia to the end of biopsy. It took 35.3 ± 18.7 minutes to obtain the pathological report of IFSE. The incidences of complication hematuria and urinary retention were 10.5% and 2.6%, respectively.ConclusionFor elderly patients with highly suspected prostate cancer, single-point prostate biopsy can be used to quickly and safely obtain pathological results.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of single-point prostate biopsy in elderly patients with highly suspected prostate cancer

Luan

Xiao²,

Ding³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Meissner and Louise et al. ( 31 , 32 )recently reported that among patients highly suspected of PCa in MPMRI and PSMA-PET, patients with strong uptake of PSMA and MRI positive could avoid definitive biopsy and directly conduct definitive treatment. Avoiding prostate biopsy before RP might be an effective choice.…”

Section: Discussionmentioning

confidence: 99%

Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study

Chen

Niu²,

Chen³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundsProstate cancer (PCa) is the second most common male cancer in the world and based on its high prevalence and overwhelming effect on patients, more precise diagnostic and therapeutic methods are essential research topics. As such, this study aims to evaluate the value of three-dimensional transrectal ultrasound (3D-TRUS) in the detection, diagnosis and biopsy of PCa, and to provide a basis for clinical practice of PCa.MethodsRetrospective analysis and comparison of a total of 401 male patients who underwent prostate TRUS in our hospital from 2019 to 2020 were conducted, with all patients having prostate biopsy. Nomogram was used to estimate the probability of different ultrasound signs in diagnosing prostate cancer. The ROC curve was used to estimate the screening and diagnosis rates of 3D-TRUS, MRI and TRUS for prostate cancer.ResultsA total of 401 patients were randomly divided into two groups according to different methods of prostate ultrasonography, namely the TRUS group (251 patients) and the 3D-TRUS group (150 patients). Of these cases, 111 patients in 3D-TRUS group underwent MRI scan. The nomogram further determined the value of 3D-TRUS for prostate cancer. The ROC AUC of prostate cancer detected by TRUS, MRI and 3D-TRUS was 0.5580, 0.6216 and 0.6267 respectively. Biopsy complications were lower in 3D-TRUS group than TRUS group, which was statistically significant (P<0.005).ConclusionsThe accuracy of 3D-TRUS was higher in diagnosis and biopsy of prostate cancer. Meanwhile, the positive rate of biopsy could be improved under direct visualization of 3D-TRUS, and the complications could be decreased markedly. Therefore, 3D-TRUS was of high clinical value in diagnosis and biopsy of prostate cancer.

show abstract

“…However, the role of molecular imaging to aid in the primary detection of localized prostate cancer has yet to be fully explored and early reports of PET and MRI image-guided, biopsy-free treatment algorithms suggest this approach is potentially feasible. 14 The primary focus of this article will be to review the nuclear medicine radiotracers used in imaging prostate cancer and their potential role as both PET/CT and PET/MRI to guide diagnosis of localized primary prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Role of molecular imaging in the detection of localized prostate cancer

Galgano

West

Rais‐Bahrami

2022

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Molecular imaging of prostate cancer continues to grow, with recent inclusion of several positron emission tomography (PET) radiotracers into the recent National Comprehensive Cancer Network guidelines and the US Food and Drug Administration approval of prostate-specific membrane antigen (PSMA)-targeted radiotracers. While much of the work for many of these radiotracers is focused on systemic staging and restaging in both newly diagnosed high-risk prostate cancer and biochemically recurrent disease patients, the potential role of molecular imaging for the detection of localized prostate cancer has not yet been fully established. The primary aim of this article will be to present the potential role for molecular imaging in the detection of localized prostate cancer and discuss potential advantages and disadvantages to utilization of both PET/computed tomography (CT) and PET/magnetic resonance imaging (MRI) for this clinical indication of use.

show abstract

Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography

Cited by 61 publications

References 10 publications

Application of single-point prostate biopsy in elderly patients with highly suspected prostate cancer

Application of single-point prostate biopsy in elderly patients with highly suspected prostate cancer

Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study

Role of molecular imaging in the detection of localized prostate cancer

Contact Info

Product

Resources

About